Jean-Marc Ferran | Qualiance

Long-term effectiveness and safety of daily growth hormone therapy in Japanese children with Noonan syndrome: a post-marketing surveillance study – Muroya et al. (Endocrine Journal, 2025)

by Jean-Marc Ferran | Aug 16, 2025 | Analytics

This analysis of GHT in Noonan Syndrome patients in Japanese children was supported by Qualiance (Co-Author) who provided statistical support to produce the underlying analyses.

Comparative Outcomes of GH Treatment in Pediatric Idiopathic Short Stature and GH Deficiency – Phillip et al. (JES, 2025)

by Jean-Marc Ferran | Aug 16, 2025 | Analytics

This comparitive analysis of GHT in GHD and ISS patients is based on the pooled analysis of the NordiNet IOS (Europe) and ANSWER (US) Paediatric Growth Hormone Programs. Qualiance (Co-Author) provided statistical support to produce the underlying analyses.

Using RWD to Inform the Next Study: a Case Study – JM. Ferran (PHUSE Strasbourg EU Connect, 2024)

by Jean-Marc Ferran | Nov 30, 2024 | Analytics

This conference presentation shares the background of an analysis of RWD from a patients registry for ISS patients, which was then used to inform the next study on predictors of response to GHT in this disease area.

Clinical Predictors of Good/Poor Response to Growth Hormone Treatment in Children with Idiopathic Short Stature – Dauber et al. (HRP, 2024)

by Jean-Marc Ferran | Nov 21, 2024 | Analytics

This analysis of Clinical Predictors for response in ISS patients is based on the pooled analysis of the NordiNet IOS (Europe) and ANSWER (US) Paediatric Growth Hormone Programs. Qualiance (Co-Author) provided statistical support to produce the underlying...

Handling missing data in exploratory analyses using RWD, ”Collect the data you love or love the data you get” – A case study – JM. Ferran (PHUSE Birmingham EU Connect, 2023)

by Jean-Marc Ferran | Nov 25, 2023 | Analytics

This conference presentation shares the background of an analysis of RWD from a patients registry for AGHD patients for CV risk, where missing data was handled carefully to produce robust analyses.

« Older Entries

Long-term effectiveness and safety of daily growth hormone therapy in Japanese children with Noonan syndrome: a post-marketing surveillance study – Muroya et al. (Endocrine Journal, 2025)

Comparative Outcomes of GH Treatment in Pediatric Idiopathic Short Stature and GH Deficiency – Phillip et al. (JES, 2025)

Using RWD to Inform the Next Study: a Case Study – JM. Ferran (PHUSE Strasbourg EU Connect, 2024)

Clinical Predictors of Good/Poor Response to Growth Hormone Treatment in Children with Idiopathic Short Stature – Dauber et al. (HRP, 2024)

Handling missing data in exploratory analyses using RWD, ”Collect the data you love or love the data you get” – A case study – JM. Ferran (PHUSE Birmingham EU Connect, 2023)

Recent Posts

Recent Comments

Archives

Categories

Meta